Fluconazole: Nursing Drug Guide, QT & Drug Interactions
Healthcare medication guide: preventing QT-related arrhythmia risk, warfarin and CYP-mediated toxicity, and hepatotoxicity when fluconazole is started, continued, or combined with interacting drugs in hospitalized and ambulatory patients.
Fluconazole can prolong QT (especially with hypokalemia and QT drugs), cause serious hepatic injury, and markedly increase warfarin effect and phenytoin levels. Reconcile interacting drugs, monitor INR, LFTs, electrolytes, and ECG when indicated, and hold with prescriber/pharmacist review when toxicity signals appear.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Reconcile warfarin, phenytoin, QT drugs, and oral hypoglycemics before every dose. Trend INR, potassium, QTc, and liver enzymes when ordered. Hold and involve pharmacy when INR spikes, LFTs climb, or QT risk accumulates—renal adjustment is mandatory for repeated doses when creatinine clearance is ≤50 mL/min.
Most common brand names
Fluconazole is widely known by the brand name Diflucan and is available as oral tablets, oral suspension, and IV formulation per institution formulary.
Common branding includes Diflucan. Combination products with fluconazole are not standard inpatient formulations—verify single-entity orders versus other azoles (itraconazole, voriconazole) on the MAR.
Why we give it — Indications
Fluconazole treats susceptible Candida and Cryptococcus infections and prevents candidiasis in selected transplant patients per FDA-approved labeling.
| Use | Detail |
|---|---|
| Vaginal candidiasis | 150 mg as a single oral dose for vulvovaginal candidiasis per labeling. |
| Oropharyngeal, esophageal, systemic Candida, cryptococcal meningitis, and transplant prophylaxis | Multi-day regimens with loading doses; duration depends on infection site and clinical response—AIDS patients may need maintenance therapy to prevent relapse. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Fluconazole selectively inhibits fungal cytochrome P450 enzyme lanosterol 14-α-demethylase, blocking ergosterol synthesis and increasing fungal membrane permeability. It is a moderate CYP2C9 and CYP3A4 inhibitor and a strong CYP2C19 inhibitor, which drives many drug interactions. Mammalian cell demethylation is much less sensitive than fungal targets.
Dosing overview
Oral and IV daily doses are equivalent because oral absorption is rapid and nearly complete. Match the regimen to indication and renal function.
Missed dose: If a scheduled dose is missed, give it when remembered unless near the next dose; do not double doses. For single-dose vaginal therapy, contact prescriber if the dose was not taken.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Bioavailability (oral) | >90% compared with IV; may be taken with or without food | Oral and IV daily doses are equivalent per labeling—do not assume poor absorption if oral route is ordered |
| Steady state | Reached within 5–10 days on once-daily dosing | Loading dose (2× daily dose on day 1) is used for multi-day regimens to approach steady state by day 2 |
| Half-life | Prolonged with renal impairment; inversely related to creatinine clearance | Renal dose reduction and dialysis timing affect next-dose safety—coordinate with pharmacy |
| Elimination | ~80% unchanged in urine; hemodialysis removes ~50% over 3 hours | Trend creatinine and verify post-dialysis dosing on hemodialysis days |
| CYP inhibition duration | Enzyme inhibition may persist 4–5 days after the last dose | Interaction risk (warfarin, phenytoin, QT drugs) continues briefly after discontinuation—document stop date for pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy to fluconazole or azoles; review prior serious azole reactions
- Renal function and need for dose adjustment on repeated dosing
- Concurrent warfarin, phenytoin, QT-prolonging drugs, oral hypoglycemics, immunosuppressants, and duplicate azole therapy
Contraindications
- Hypersensitivity to fluconazole or formulation excipients
- Coadministration with quinidine (contraindicated)
- Coadministration with other drugs that prolong QT and are metabolized by CYP3A4 when prohibited by prescriber/pharmacy plan (e.g., erythromycin, pimozide per labeling)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Warfarin and coumarin anticoagulants | Increased prothrombin time and bleeding risk | Monitor INR; teach bleeding precautions; notify prescriber/pharmacist for dose adjustment |
| Phenytoin, carbamazepine, theophylline | Increased levels of narrow therapeutic index drugs | Monitor levels and toxicity signs; pharmacy review before starting fluconazole |
| QT-prolonging agents (e.g., amiodarone) and hypokalemia | Additive QT prolongation; torsade de pointes risk | Correct potassium; ECG monitoring per orders; avoid prohibited combinations |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or suspension; IV infusion per institution protocol
- Oral doses may be given without regard to meals
- Verify renal-adjusted dose on MAR before administering repeated doses
- Document interaction monitoring plan when warfarin or phenytoin is concurrent
Fluconazole inhibits CYP enzymes for several days after the last dose. Starting or stopping fluconazole in a patient on warfarin, phenytoin, sulfonylureas, or QT-prolonging therapy requires proactive INR, level, glucose, and cardiac monitoring per pharmacy and prescriber plan.
Expected therapeutic response
- Decreasing oral or esophageal candidiasis symptoms over days with appropriate regimen
- Improving culture or clinical markers for systemic Candida or cryptococcal disease per prescriber targets
- Symptom relief after single-dose vaginal therapy within days; recurrence may need reassessment
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Headache, nausea, abdominal pain, diarrhea | Common with single-dose vaginal regimen and multi-dose therapy | Document tolerance; differentiate from drug toxicity; support hydration |
| Hepatotoxicity (transaminase rise to hepatitis, cholestasis, fulminant failure) | Rare but serious; fatalities reported mainly in seriously ill patients | Trend liver function tests per orders; hold and notify prescriber if clinical hepatitis or marked LFT rise |
| QT prolongation / torsade de pointes | Rare post-marketing; often with confounding QT risk factors | Monitor electrolytes and ECG when ordered; avoid concomitant QT-prolonging drugs when contraindicated |
| Rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS | Uncommon to rare | Stop fluconazole for progressive rash; urgent escalation for mucosal involvement or systemic symptoms |
| Anaphylaxis / angioedema | Rare | Stop drug; emergency airway and allergy pathway per protocol |
| Bleeding with warfarin or other coumarin anticoagulants | Post-marketing reports with increased prothrombin time | Monitor INR and bleeding cues; patient teaching on bruising and bleeding |
| Hypoglycemia with sulfonylureas | Clinically significant hypoglycemia reported; one fatality with glyburide | Monitor blood glucose when oral hypoglycemics are concurrent |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose reports describe hallucination and paranoid behavior. Management is symptomatic with supportive measures and gastric lavage if clinically indicated. Fluconazole is largely excreted in urine; a 3-hour hemodialysis session decreases plasma levels by approximately 50%.
Nursing actions
- Stop further doses and notify prescriber/pharmacist and poison control or toxicology services per facility protocol
- Monitor mental status, cardiac rhythm (QT), and renal function
- Prepare for hemodialysis discussion when severe toxicity and renal failure coexist per medical team
Contact local poison control or medical toxicology services for guidance on large ingestions or serious cardiac, hepatic, or neurologic toxicity.
Antidote: Not specified in the reviewed prescribing information — treatment is supportive; no specific reversal agent is listed.
Look-alike / sound-alike and error prevention
- Fluconazole vs flucytosine — different antifungals with distinct toxicity profiles; verify name and dose on MAR and vial
- Fluconazole vs fluoxetine — sound-alike risk in verbal/telephone orders; read back generic and brand (e.g., Diflucan)
- Oral vs IV fluconazole — daily dose is the same route-to-route per labeling, but infusion line and rate checks still apply for IV products
- 150 mg single dose vs 200–400 mg daily — vaginal candidiasis uses one 150 mg dose; systemic infections use higher multi-day regimens
- Diflucan (fluconazole) vs topical azoles — systemic therapy is not interchangeable with topical clotrimazole or nystatin for deep or immunocompromised infection
- Perform medication reconciliation at admission and transfer to catch duplicate azoles or interacting drugs (warfarin, phenytoin, QT agents)
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Before first dose | Reconcile MAR with allergy history, renal function, LFTs, QT-risk drugs, anticoagulants, and oral hypoglycemics |
| Oral administration | May give with or without food; swallow tablets whole unless institution crushes per pharmacy policy |
| IV administration | Follow institution IV azole protocol for rate and compatibility; oral bioavailability is high when switching routes |
| Renal impairment | After loading dose, give 50% of daily dose when creatinine clearance ≤50 mL/min; 100% after each hemodialysis session |
| Warfarin patients | Expect closer INR monitoring when fluconazole starts or stops; teach bleeding precautions |
| Ask pharmacy when | Unclear renal adjustment, multiple CYP interactions, rising INR or LFTs, or duplicate systemic azole orders |
On a small screen, swipe or scroll sideways to see the full table.
Red flags — Stop and act
Stop fluconazole and escalate when life-threatening toxicity or interaction complications develop.
- Signs of bleeding or INR markedly above therapeutic range on warfarin
- Palpitations, syncope, or documented torsade de pointes / severe QT prolongation
- Jaundice, dark urine, right upper quadrant pain, or rapidly rising transaminases
- Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (severe rash with fever, eosinophilia, organ involvement)
- Anaphylaxis (wheezing, angioedema, hypotension)
High-risk populations
| Population | Considerations |
|---|---|
| Patients on warfarin or other interacting narrow-index drugs | Highest bleeding and toxicity risk when fluconazole starts or dose increases—coordinate INR and level checks |
| Renal impairment and hemodialysis | Accumulation and prolonged half-life increase toxicity and interaction duration—pharmacy must verify adjusted doses |
| Critical illness with hypokalemia, cardiac disease, or multiple QT drugs | Proarrhythmic conditions increase torsade de pointes risk per labeling |
| Pregnancy | Avoid except for severe life-threatening fungal infections when benefit outweighs fetal risk; high-dose first-trimester exposure has been associated with distinct congenital anomalies in case reports. Effective contraception should be considered during high-dose therapy per labeling. |
| Lactation | Fluconazole is present in breast milk after a single 150 mg dose; caution in nursing mothers. LactMed notes low levels after single dose but advises monitoring the infant if repeated or high-dose therapy is used. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- INR and signs of bleeding when warfarin or coumarins are concurrent
- Liver function tests and clinical signs of hepatotoxicity on multi-day therapy
- Potassium, magnesium, and electrocardiogram/QTc when QT-risk drugs or electrolyte abnormalities are present
Document
- Dose, route, indication, and renal adjustment verification
- Interaction alerts communicated to prescriber/pharmacy and patient teaching provided
- Hold events, adverse effects, INR/LFT trends, and dialysis timing for dose administration
Patient teaching
- Report bruising, bleeding gums, black stools, or vomiting blood immediately when on anticoagulants
- Report rash, yellow skin or eyes, severe nausea, palpitations, or fainting
- Take oral doses as directed; do not stop early without prescriber advice except for serious reactions
- Tell all clinicians you are taking fluconazole before new prescriptions are added
- Effective contraception during high-dose therapy if of childbearing potential per prescriber counseling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity or anaphylaxis to fluconazole or azoles
- Supratherapeutic INR, active bleeding, or prescriber/pharmacist hold for warfarin interaction
- Clinical hepatitis, jaundice, or rapidly worsening liver function tests attributable to fluconazole
- Symptomatic severe QT prolongation or torsade de pointes until cardiology/prescriber review
- Creatinine clearance ≤50 mL/min without a verified reduced dose order for repeated dosing
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Safe fluconazole administration depends on interaction screening at admission and reassessment whenever interacting drugs are added or renal function changes.
1. Check-before-you-give protocol
- Confirm indication-appropriate dose (single 150 mg vs multi-day systemic regimen)
- Verify renal-adjusted MAR entry and dialysis timing for inpatients on hemodialysis
- Review latest INR, LFTs, potassium, and ECG results when clinically relevant
- Check for contraindicated QT combinations flagged by pharmacy
2. High-alert and safety badge
Major interaction / QT riskNot a traditional high-alert medication list drug, but fluconazole carries serious interaction, QT, and hepatotoxicity warnings that require the same disciplined double-checks as high-alert therapies when warfarin, phenytoin, or QT drugs are present.
3. Clinical workflow: hold and question rules
- Hold for rising INR or bleeding until prescriber/pharmacist plan
- Hold for transaminase doubling or clinical jaundice pending hepatology/prescriber review
- Do not administer standard repeated dose when renal adjustment is required but missing
4. Critical teach-back questions
- “What bleeding signs will you report while taking fluconazole with warfarin?” Unusual bruising, bleeding gums, nosebleeds, black stools, or vomiting blood.
- “Why must you tell providers about fluconazole before starting new medicines?” Because fluconazole interacts with many drugs and can raise toxicity and bleeding risk.
5. Care coordination
Pharmacist: Renal and interaction review, INR/level monitoring plans, and therapeutic duplication checks when fluconazole starts or stops
Infectious diseases / primary prescriber: Culture-directed therapy, duration of treatment, and switching antifungals when resistance or toxicity occurs
🧠 Quick mental checklist
- Is this the correct dose for the indication and renal function?
- Are warfarin, phenytoin, QT drugs, or sulfonylureas on the MAR?
- What are today’s INR, LFTs, potassium, and QTc results?
- Does the patient have rash, jaundice, palpitations, or bleeding?
- Has pharmacy verified renal and interaction plan?
Fluconazole NCLEX practice questions
This NCLEX-style clinical judgment practice set for fluconazole uses a tabbed case (MAR, labs, vitals/ECG, nursing notes) with warfarin interaction and QT/hepatic risk, then rotates priority action, cue recognition, trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, Vitals / ECG, and nursing note details for this case.
- Fluconazole 100 mg PO daily — day 5 of oropharyngeal candidiasis regimen (200 mg loading on day 1 per order)
- Warfarin 5 mg PO daily — continued; INR due 1400
- Potassium chloride 40 mEq PO daily — ordered for hypokalemia
- Amiodarone 200 mg PO daily — home medication reconciled yesterday
- INR: 2.1 (yesterday) → 3.6 (today 0600) — goal 2–3
- AST 32 → 98 U/L; ALT 28 → 112 U/L (48 h trend)
- Potassium 3.1 mEq/L (today); magnesium 1.6 mg/dL
- Creatinine 1.4 mg/dL; eGFR 48 mL/min (was 62 mL/min admission)
- BP 118/72; HR 88; afebrile
- ECG: QTc 472 ms (prior 438 ms on admission)
- SpO₂ 97% on room air
- Patient reports new nosebleed and lightheadedness
- 0200: Small epistaxis controlled with pressure; no formal bleeding protocol yet
- 0900: Patient asked why “heart medicine” and fluconazole were started same week—teaching incomplete
- 1200: Pharmacy sticker on chart: fluconazole–warfarin interaction; INR not rechecked after fluconazole day 3
Answer key & rationale
Frequently asked questions
What should nurses check before giving fluconazole?
Review allergies to azoles, current renal function (creatinine clearance), liver function tests, concurrent QT-prolonging or CYP-interacting drugs (warfarin, phenytoin, certain antiarrhythmics, sulfonylureas), and pregnancy status for high-dose regimens. Verify the indication matches the dose (single 150 mg for vaginal candidiasis vs higher multi-day therapy for systemic infection).
When should a nurse hold fluconazole?
Hold for hypersensitivity, clinical signs of liver injury, rapidly rising transaminases attributable to fluconazole, supratherapeutic INR or bleeding on concurrent warfarin until prescriber/pharmacist review, new QT prolongation with concerning arrhythmia symptoms, and severe hypokalemia or electrolyte instability until corrected per prescriber. Do not give the standard dose when renal-adjusted orders are required but not yet verified.
Does fluconazole interact with warfarin?
Yes. Prescribing information and post-marketing data report increased prothrombin time and bleeding events when fluconazole is given with coumarin anticoagulants such as warfarin. Nurses should monitor INR more closely, teach bleeding precautions, and escalate rising INR or bruising to the prescriber and pharmacist.
How is fluconazole dosed in renal impairment?
Single 150 mg therapy for vaginal candidiasis does not require adjustment for renal impairment per labeling. For repeated doses, give a loading dose then reduce to 50% of the usual daily dose when creatinine clearance is 50 mL/min or less. Hemodialysis patients receive 100% of the recommended dose after each dialysis session and a reduced dose on non-dialysis days per creatinine clearance.
Is fluconazole safe in pregnancy and breastfeeding?
High-dose fluconazole (400–800 mg/day) in the first trimester has been associated with distinct congenital anomalies in case reports; use in pregnancy should be avoided except for severe life-threatening infections when benefit outweighs risk. A single 150 mg dose has epidemiologic limitations in pregnancy data. Fluconazole enters breast milk after a single 150 mg dose; caution is advised in nursing mothers per labeling and LactMed.
References
-
U.S. National Library of Medicine. Fluconazole tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c924c51c-ed7e-7e72-e053-2995a90adcd3
-
Pappas PG, et al. Infectious Diseases Society of America. Clinical Practice Guideline for the Management of Candidiasis.https://www.idsociety.org/practice-guideline/candidiasis/
-
Drugs and Lactation Database (LactMed). Fluconazole. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK519016/
-
U.S. Food and Drug Administration. Diflucan (fluconazole) label — historical reference. FDA Drug Labels.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019949s072lbl.pdf
-
U.S. Food and Drug Administration. Diflucan (fluconazole) tablets — Prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019949s072lbl.pdf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.